On October 16, 2025, NovaBay Pharmaceuticals, Inc. approved a plan for a reverse stock split of shares and the conversion of preferred stock to common stock, resulting in the issuance of up to 120 million shares. This follows a $9.85 million stock sale agreement with investors and signifies a change in control of the company.